Altraide v. Eyolfson CA3
This case arises out of decedent’s treatment for prostate cancer at a Kaiser medical facility. Decedent died in May 2015, and this action was filed in May 2018 against various Kaiser entities, decedent’s primary care physician, and three additional doctors and a nurse who were involved in his cancer treatment. In 2019, decedent’s wife, their children, and their daughter-in-law filed the operative complaint, which added three pharmaceutical companies and two additional nurses as defendants. The pharmaceutical defendants included the two companies that allegedly manufactured Lupron, and a third company that allegedly manufactured Effexor.
This is the second appeal in this case.
Comments on Altraide v. Eyolfson CA3